<DOC>
	<DOCNO>NCT00177138</DOCNO>
	<brief_summary>This single center , prospective , open-label , randomized trial University Minnesota Medical Center , Fairview . Primary objectives determine rejection episodes loss rate , graft survival , level renal graft function , patient survival rate Campath/MMF-based ( Group 1 ) immunosuppressive protocol lower , equal , protocol use thymoglobulin , tacrolimus , MMF ( Group 2 ) . This study investigate first protocol steroid-free calcineurin inhibitor-free pancreas kidney transplant recipient .</brief_summary>
	<brief_title>Use Campath Induction Maintenance Therapy Pancreas After Kidney Transplantation</brief_title>
	<detailed_description>Secondary objective study : 1 . Compare side effect immunosuppressive medication group . This include anaphylactic reaction , GI side-effects , bone marrow suppression , renal dysfunction , hypertension , hyperglycemic effect , effect lipid profile . 2 . Compare incidence infection group . Comparison parameter : 1 . Pancreas kidney graft failure 2 . Patient death 3 . Clinical biopsy document rejection episodes 4 . Patient dropout ( non-compliance study protocol ) 5 . Kidney function assess creatinine clearance biopsy 6 . Need change immunosuppression regimen 7 . Quality-adjusted Life Years</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>1 . Previous kidney transplant living decease donor decease donor pancreas transplant . 2 . Recipient age 1860 year 3 . Donor age 1059 year 4 . Females childbearing potential negative pregnancy test , agree practice birth control duration study . 5 . Enteric bladder drain pancreas transplant . 1 . Use investigational drug last 1year . 2 . Positive T B cell crossmatch . 3 . WBC &lt; 3000 enrollment 4 . Platelet count &lt; 50,000 enrollment 5 . History malignancy ( exclusive minor skin cancer ) 6 . Inability give inform consent 7 . Systemic infection 8 . Major active chronic infection , include document HIV infection ( licensed ELISA confirmation Western Blot ) . 9 . Serology negative EBV pretransplant . 10 . No previous organ transplant pancreas and/or kidney .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Campath Study</keyword>
	<keyword>Pancreas After Kidney Transplantation</keyword>
	<keyword>Alemtuzumab</keyword>
</DOC>